×

Government Agencies FDA

  • Sarepta delays filing muscular dystrophy drug

    The FDA wants more data on the new drug, reports CNBC's Meg Tirrell with the latest details.

  • Chimerix gets FDA approval

    Chimerix says it has FDA approval to test its experimental anti-viral drug on Ebola patients, reports CNBC's Dominic Chu.

  • GW Pharma: Focused on epilepsy

    GW Pharma shares are down sharply after a study of its treatment for ulcerative colitis missed its primary endpoint in a mid-stage trial. GW Pharmaceuticals CEO Justin Gover, says the company's main focus is on its product for epilepsy.

  • Obama: US working on Ebola screening

    CNBC's Meg Tirrell looks at the screening protocols the U.S. is considering to stop Ebola from entering the country.

  • Battling Ebola

    CNBC's Meg Tirrell, and Dr. Moncef Slaoui, GlaxoSmithKline, discuss the latest efforts to develop an Ebola vaccine.

  • Dallas Ebola patient to get experimental drug

    CNBC's Meg Tirrell reports the FDA has given permission for drugmaker Chimerix to provide an antiviral drug to Thomas Eric Duncan, as President Obama looks at ways to strengthen passenger screening for Ebola.

  • FDA approves non-invasive colon cancer screening test

    Kevin Conroy, Exact Sciences chairman & CEO, provides details on a potential major breakthrough in the fight against colon cancer.

  • A cancer pharmacology research investigator prepares tissue cultures.

    The FDA approved the first screening test for colon cancer that uses patients' DNA to help spot potentially deadly tumors and growths.

  • AG Zoeller urges FDA to regulate e-cigs

    Indiana Attorney General Greg Zoeller, has joined the fight to urge the FDA to strengthen electronic cigarette regulations and adopt new policies to protect minors from harmful flavoring and addictive electronic cigarettes.

  • Clearing FDA hurdles

    Scott Gottlieb, M.D., American Enterprise Institute, explains why he thinks excessive FDA regulations are stalling innovation in medical technology.

  • Gaining access to experimental drugs

    Scott Gottlieb, M.D., American Enterprise Institute, and Jeff Allen, Friends of Cancer Research executive director, discuss the FDA's drug approval process and the need in some cases to allow access to experimental therapies.

  • Nathalie Traller back in the clinic.

    Terminally ill patients are increasingly seeking access experimental drugs outside clinical trials, but drug companies often decline these requests. A look at why.

  • A pharmacist searches for drugs in a pharmacy in Lagos, Nigeria, July, 2014.

    A dose of experimental serum arrived in Liberia to be tried on a U.S. charity worker—but there was only enough for one of the two infected workers, NBC.

  • A researcher takes tissue samples from genetically modified corn plants.

    The way consumers would be informed when their food has been genetically engineered is being battled in Congress and among advocacy groups.

  • Pills

    U.S. generic drug rules have been manipulated by brand-name drug companies to keep cheaper competition off the market, a report says.

  • Research's 'transformational' cures for blindness

    Gordon Gund, Gund Investment Corp. chairman & CEO, who lost his sight 40 years ago, discusses the promising work being done to find a cure for blindness.

  • Finding the cure for blindness

    Gordon Gund, Gund Investment Corp. chairman & CEO, who lost his sight 40 years ago, discusses his goal to raise $100 million to fund research for a cure for blindness.

  • FDA ruling a win for paraplegic community

    Larry Jasinski, ReWalk Robotics CEO, discusses how the FDA's decision will likely improve the lives of wheelchair bound people. This is such groundbreaking technology that the FDA put a new classification code for this product, explains Jasinski.

  • The U.S. Food and Drug Administration warned that popular acne products can cause rare but serious and life-threatening allergic reactions.

  • Cubist advances Sivextro

    Michael Bonney, Cubist Pharmaceuticals CEO, discusses the FDA's approval of Sivextro, a new antibiotic designed to treat skin infections. Bonney also explains why so many pharma companies have left the antibiotic space.